Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accretion NutravedaBOM:544694 21 Days Payable is 23.39 as of Mar. 2026, which is 73% below its 10-year median of 86.67. GuruFocus rates BOM:544694 with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 927 Drug Manufacturers companies, Accretion Nutraveda ranks worse than 93.85% on this metric.
The historical rank and industry rank for Accretion Nutraveda's Days Payable or its related term are showing as below:
BOM:544694'
s Days Payable Range Over the Past 10 Years
Min: 13.56 Med: 86.67 Max: 316.78
Current: 22.89
During the past 4 years, Accretion Nutraveda's highest Days Payable was 316.78. The lowest was 13.56. And the median was 86.67.
BOM:544694's Days Payable is ranked worse than 93.85% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.28
vs BOM:544694: 22.89
Accretion Nutraveda's Days Payable
increased
from Mar. 2025 (21.98) to Mar. 2026 (23.39).
It may suggest that Accretion Nutravedadelayed paying its suppliers.
The historical data trend for Accretion Nutraveda's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Nutraveda Days Payable Chart
Accretion Nutraveda Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
Days Payable
316.78
142.57
30.77
13.56
Accretion Nutraveda Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
Mar26
Days Payable
0.00
0.00
21.98
33.91
23.39
BOM:544694 vs ZTS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Accretion Nutraveda's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Nutraveda Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Nutraveda's Days Payable distribution charts can be found below:
* The bar in red indicates where Accretion Nutraveda's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Accretion Nutraveda's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Nutraveda (BOM:544694) has a Days Payable of 23.39 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Accretion Nutraveda and its competitors. This is 73% below median its historical median of 86.67. Over the past decade, Accretion Nutraveda's Days Payable has ranged from 13.56 to 316.78. According to the industry distribution chart, Accretion Nutraveda ranks #870 out of 927 companies in the Drug Manufacturers industry, placing it in the top 93.9%.
Is Accretion Nutraveda's Days Payable too high?
Accretion Nutraveda's current Days Payable of 23.39 is 73% below median its 10-year median of 86.67. Over the past 10 years, this metric has ranged from a low of 13.56 to a high of 316.78. The Drug Manufacturers industry median Days Payable is 90.28. Accretion Nutraveda's value of 23.39 is 74.1% below this industry median. Based on the distribution chart, Accretion Nutraveda ranks #870 out of 927 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Accretion Nutraveda has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Nutraveda's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Accretion Nutraveda ranks #870 out of 927 companies for Days Payable. This places Accretion Nutraveda in the lower half of its industry. The industry median Days Payable is 90.28. Accretion Nutraveda's value of 23.39 is 74.1% below this benchmark. Historically, Accretion Nutraveda's own Days Payable has ranged from 13.56 to 316.78 over the past decade. While the company's 10-year median is 86.67 vs. the industry median of 90.28, Accretion Nutraveda has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.28, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accretion Nutraveda's current Days Payable of 23.39 is 74.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Accretion Nutraveda and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Nutraveda's current Days Payable is 23.39, which is 73% below median its own 10-year median of 86.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Nutraveda stock overvalued right now?
Accretion Nutraveda (BOM:544694) has a current Days Payable of 23.39. The current Days Payable is 23.39, which is 73% below median its 10-year median of 86.67 and 74.1% below the Drug Manufacturers industry median of 90.28. Accretion Nutraveda's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Accretion Nutraveda (BOM:544694), the current Days Payable is 23.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Nutraveda Ltd is engaged in the business of the Manufacturing of Ayurvedic and Nutraceutical products across several dosage forms, including Tablets, Capsules, Oral liquids, Oral Powders, External Preparation and Oils. It is a healthcare focused Company specializing in contract manufacturing, serving domestic as well as export markets in various countries like Sri Lanka, Singapore and the USA. The company offers a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science. Its product portfolio includes Tablets, such as film-coated and chewable varieties, for applications in liver care, gynecological care, bone and joint health, and respiratory support.
21GF Score
Get the complete analysis for BOM:544694
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544694 has been successfully added to your 
